Pharmaceutical Product Development (PPD) has announced that Michael Gold, M.D., has joined PPD’s neuroscience team to serve as vice president of global product development, strengthening the company's ability to help biopharmaceutical clients manage the complex world of nervous system disorders and deliver therapies more efficiently and cost-effectively.
“Mike adds impressive depth to PPD’s neuroscience medical team, which offers expertise across a range of disorders,” said Rob Dow, senior vice president, global product development for PPD. “Mike’s broad experience in the development of new medicines spans a variety of neurologic conditions, and his expertise in the field of neurodegenerative diseases, including Alzheimer’s and other forms of dementia, is of great value to our clients, as we work together to advance treatment options for these debilitating diseases.”
PPD has successfully managed approximately 285 trials in psychiatry, neurology, pain and ophthalmology indications across all phases of development. PPD’s clinical team and medical professionals provide strong experience in disorders of the central nervous system (CNS), peripheral nervous system, sleep medicine and pain management. These clinically trained neuroscience teams are led by senior scientists and clinicians with extensive drug development experience in the areas of neurology, psychiatry, pain management, sleep research and ophthalmology.
Gold joined PPD after serving in leadership roles in major pharmaceutical and biotech companies, as well as academia. Most recently, Gold spent two years at UCB Biosciences as vice president of global therapeutic area, central nervous system. Previously, he worked for nearly three years at Allon Therapeutics as vice president and chief medical officer. From 2005 to 2011, Gold was with GSK, where he served as medicines development leader for Alzheimer’s disease and vice president of neurosciences, medicines development center. Earlier in his career, he held positions of increasing responsibility within clinical research at Johnson & Johnson and Bristol-Myers Squibb.
